Bayer to license Cedilla’s selective inhibitors in precision oncology
The license agreement provides Bayer with exclusive rights to develop and commercialise Cedilla’s CyclinE1/CDK2 inhibitors that are currently…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Jun 23
The license agreement provides Bayer with exclusive rights to develop and commercialise Cedilla’s CyclinE1/CDK2 inhibitors that are currently…
01 Jun 23
Cobitolimod, a TLR9 agonist, is currently undergoing evaluation in the global phase III programme, known as CONCLUDE, as…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 May 23
Astellas and Sony will jointly develop and optimise a new ADC platform using KIRAVIA Backbone as a linker,…
16 May 23
Arcus will receive an upfront payment of $35m and will commence research programs against up to four targets,…
12 May 23
Bentracimab is a novel, monoclonal antibody fragment that reverses the antiplatelet activity of ticagrelor, an antiplatelet medicine marketed…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
08 May 23
The biotechnology company has entered negotiations with a major global pharmaceutical company, for the development and commercialisation of…
05 May 23
Under the terms of the agreement, Novocol Pharma will provide fill-finish and packaging for vaccines manufactured at Moderna’s…
08 Mar 23
The financing, led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly, will support Volastra’s portfolio…
28 Oct 22
Under the agreement, FDB will provide drug substance manufacturing of efgartigimod at its large-scale biomanufacturing facility in Hillerød,…
09 Sep 22
The collaboration will combine AstraZeneca’s expertise in RNA therapeutics with Gatehouse Bio’s capabilities in small RNA compounds to…